American Heart Association 2003 Scientific Sessions In Brief
This article was originally published in The Gray Sheet
Executive Summary
Arrow takes aim at Thoratec data: Adverse event rate associated with Arrow International's LionHeart left-ventricular assist device in the European Clinical Utility Baseline Study (CUBS) is comparable to Thoratec's HeartMate VE in the REMATCH trial, Arrow contends. Results of the destination LVAD therapy trial were presented by John Boehmer, MD, Pennsylvania State University, at the American Heart Association annual scientific sessions in Orlando Nov. 10. In CUBS, LionHeart was associated with 7.56 adverse events per patient-year, compared with 6.39 in REMATCH. Boehmer notes, however, that CUBS represents LionHeart's first clinical experience, while HeartMate had been implanted in 1,000 patients as a bridge to transplant prior to REMATCH (1"The Gray Sheet" June 30, 2003, In Brief)...
You may also be interested in...
Taxus Set To Dominate? “Not So Fast,” Physicians Argue At Cordis ACC Event
Johnson & Johnson/Cordis will emphasize long-term data for its Cypher drug-eluting stent to counter the hype surrounding Boston Scientific's launch of Taxus
Taxus Set To Dominate? “Not So Fast,” Physicians Argue At Cordis ACC Event
Johnson & Johnson/Cordis will emphasize long-term data for its Cypher drug-eluting stent to counter the hype surrounding Boston Scientific's launch of Taxus
Arrow International’s Carl Anderson
Newly appointed chairman and CEO will succeed Marlin Miller Sept. 1. Anderson currently is vice chairman of Arrow and general manager of the firm's critical care business. The exec has been a director since 1998 and has served with ABC School Supply, Inc., James River Corp. and Procter & Gamble. Miller, who has been with Arrow since 1975, will continue as a director and chairman emeritus. Arrow expects a CE mark for its LionHeart left-ventricular assist device within weeks...